Plasma Therapy of COVID-19 in Severely Ill Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This randomized blinded multi-center phase 2 trial will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma among adults with severe COVID-19. Adults ≥18 years of age may participate. A total of 219 eligible subjects will be randomized in a 2:1 ratio to receive either high-titer anti-SARS-CoV-2 plasma or non-convalescent fresh frozen plasma (control plasma).
Epistemonikos ID: e7b4605dc757b67cf77988de89db4ab7fd3ebfb9
First added on: Apr 25, 2020